AMRX R&D to Revenue
Amneal Pharmaceuticals Inc Class A · R&D to Revenue
AMRX R&D to Revenue
Latest reported5.16%period ending
AMRX Quarterly R&D/Revenue (14.57% → 5.16%)
Latest values, visible window
High-resolution chart · PNG
AMRX r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 5.1625% | |
| 5.3124% | |
| 4.2758% | |
| 8.0753% | |
| 6.8986% | |
| 6.0118% | |
| 7.6818% | |
| 8.6975% | |
| 5.286% | |
| 5.9615% | |
| 7.5471% | |
| 6.8159% | |
| 6.4468% | |
| 7.2343% | |
| 7.0961% | |
| 9.4667% | |
| 9.2194% | |
| 10.7634% | |
| 9.8745% | |
| 9.5639% | |
| 10.1348% | |
| 10.4976% | |
| 11.2073% | |
| 8.9839% | |
| 10.5716% | |
| 7.552% | |
| 13.3454% | |
| 10.762% | |
| 12.4868% | |
| 13.0064% | |
| 12.167% | |
| 9.9478% | |
| 13.1425% | |
| 17.7278% | |
| 15.7569% | |
| 18.8495% | |
| 20.0523% | |
| 17.4667% | |
| 14.5735% |